The long-term management of diabetes is intensely focused on preventing its devastating chronic complications, which affect both small (microvascular) and large (macrovascular) blood vessels. A pharmacist’s role, as detailed in the Patient Care 5 curriculum, is crucial in implementing evidence-based strategies to mitigate the risk of nephropathy, retinopathy, neuropathy, and cardiovascular disease. This quiz will test your knowledge on the screening, prevention, and pharmacologic management of these life-altering conditions.
1. Diabetic retinopathy, nephropathy, and neuropathy are collectively known as what type of complications?
- a. Macrovascular complications
- b. Microvascular complications
- c. Acute complications
- d. Non-specific complications
Answer: b. Microvascular complications
2. Which class of medications is recommended first-line for a patient with diabetes and hypertension, particularly if albuminuria is present?
- a. Beta-blockers
- b. Thiazide diuretics
- c. ACE Inhibitors or ARBs
- d. Non-dihydropyridine calcium channel blockers
Answer: c. ACE Inhibitors or ARBs
3. What is the most important intervention to prevent or delay the onset of all chronic diabetic complications?
- a. Daily aspirin therapy
- b. Intensive glycemic control
- c. High-dose statin therapy
- d. A low-carbohydrate diet
Answer: b. Intensive glycemic control
4. A patient with diabetes complains of burning and tingling pain in their feet in a “stocking-glove” distribution. This is a classic symptom of:
- a. Peripheral artery disease
- b. Diabetic peripheral neuropathy
- c. Autonomic neuropathy
- d. Diabetic retinopathy
Answer: b. Diabetic peripheral neuropathy
5. Which of the following is considered a first-line pharmacologic treatment for painful diabetic neuropathy?
- a. Opioid analgesics
- b. NSAIDs
- c. Pregabalin or duloxetine
- d. Acetaminophen
Answer: c. Pregabalin or duloxetine
6. The “Management of Diabetes Complications” is a specific lecture in which course?
- a. PHA5787C Patient Care 5
- b. PHA5104 Sterile Compounding
- c. PHA5703 Pharmacy Law and Ethics
- d. PHA5878C Patient Care 3
Answer: a. PHA5787C Patient Care 5
7. How often should a patient with Type 2 Diabetes have a dilated and comprehensive eye exam?
- a. Every 5 years
- b. Only if they experience vision changes
- c. Annually
- d. Every month
Answer: c. Annually
8. The earliest clinical evidence of diabetic nephropathy is:
- a. An elevated serum creatinine.
- b. The presence of microalbuminuria.
- c. A decrease in GFR.
- d. The presence of glucose in the urine.
Answer: b. The presence of microalbuminuria.
9. In addition to an ACE inhibitor or ARB, which class of diabetes medication has shown significant benefit in slowing the progression of diabetic kidney disease?
- a. Sulfonylureas
- b. DPP-4 inhibitors
- c. SGLT2 inhibitors
- d. Insulin
Answer: c. SGLT2 inhibitors
10. According to ADA guidelines, most adults aged 40-75 with diabetes should be on what medication for primary prevention of atherosclerotic cardiovascular disease (ASCVD)?
- a. Aspirin
- b. A moderate- or high-intensity statin
- c. A fibrate
- d. A beta-blocker
Answer: b. A moderate- or high-intensity statin
11. The pathophysiology and management of diabetes is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
12. Gastroparesis is a form of which type of diabetic neuropathy?
- a. Peripheral neuropathy
- b. Autonomic neuropathy
- c. Focal neuropathy
- d. Proximal neuropathy
Answer: b. Autonomic neuropathy
13. Which of the following is a key component of diabetic foot care?
- a. Walking barefoot at home to strengthen the feet.
- b. Soaking feet in hot water daily.
- c. Performing a daily self-exam of the feet to check for cuts, sores, or blisters.
- d. Using sharp instruments to remove calluses.
Answer: c. Performing a daily self-exam of the feet to check for cuts, sores, or blisters.
14. Aspirin therapy (81 mg) for primary prevention of ASCVD in patients with diabetes:
- a. Is recommended for all patients with diabetes.
- b. May be considered for patients at high cardiovascular risk after a discussion of the risks (bleeding) and benefits.
- c. Is no longer recommended for any patient.
- d. Is used to treat neuropathy.
Answer: b. May be considered for patients at high cardiovascular risk after a discussion of the risks (bleeding) and benefits.
15. Educating a patient on how to monitor their blood glucose is a key objective for student pharmacists.
- a. True
- b. False
Answer: a. True
16. What is the recommended blood pressure goal for most patients with diabetes and hypertension?
- a. < 150/100 mmHg
- b. < 140/90 mmHg
- c. < 130/80 mmHg
- d. < 120/80 mmHg
Answer: c. < 130/80 mmHg
17. The pharmacology of injectable diabetes medications is a topic within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
18. Which of the following is considered a macrovascular complication of diabetes?
- a. Retinopathy
- b. Nephropathy
- c. Coronary Artery Disease
- d. Neuropathy
Answer: c. Coronary Artery Disease
19. A patient with diabetes has their urine albumin-to-creatinine ratio (UACR) checked annually to screen for:
- a. Retinopathy
- b. Neuropathy
- c. Nephropathy
- d. Peripheral artery disease
Answer: c. Nephropathy
20. An active learning session on diabetes complications is part of the Patient Care 5 course.
- a. True
- b. False
Answer: a. True
21. The primary mechanism by which hyperglycemia causes chronic complications is through:
- a. The production of advanced glycation end-products (AGEs).
- b. Activation of the polyol pathway.
- c. Increased oxidative stress.
- d. All of the above.
Answer: d. All of the above.
22. A patient with gastroparesis might experience:
- a. Rapid digestion and diarrhea.
- b. Nausea, vomiting, and unpredictable blood glucose levels due to delayed gastric emptying.
- c. Increased appetite.
- d. Severe constipation.
Answer: b. Nausea, vomiting, and unpredictable blood glucose levels due to delayed gastric emptying.
23. Counseling a patient on lifestyle modifications is a key objective for student pharmacists.
- a. True
- b. False
Answer: a. True
24. An active learning session on diabetes is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
25. Which of the following is NOT a first-line treatment for painful diabetic neuropathy?
- a. Duloxetine
- b. Pregabalin
- c. Gabapentin
- d. Morphine
Answer: d. Morphine
26. The leading cause of end-stage renal disease (ESRD) in the United States is:
- a. Hypertension
- b. Polycystic kidney disease
- c. Diabetic nephropathy
- d. Glomerulonephritis
Answer: c. Diabetic nephropathy
27. Proliferative diabetic retinopathy is more severe than non-proliferative because it involves:
- a. The growth of new, fragile blood vessels (neovascularization).
- b. The presence of microaneurysms only.
- c. Cotton wool spots.
- d. Macular edema only.
Answer: a. The growth of new, fragile blood vessels (neovascularization).
28. An active learning session on diabetes is part of which course module?
- a. Module 1: Diabetes Mellitus
- b. Module 3: Women’s Health
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 1: Diabetes Mellitus
29. The pharmacist’s role in preventing diabetic complications includes:
- a. Promoting adherence to medications.
- b. Encouraging smoking cessation.
- c. Reminding patients about necessary annual screenings.
- d. All of the above.
Answer: d. All of the above.
30. The “Management of Diabetes Complications” is a lecture within the Patient Care 5 curriculum.
- a. True
- b. False
Answer: a. True
31. A patient with diabetes and peripheral neuropathy should be counseled to:
- a. Always wear properly fitting shoes and never go barefoot.
- b. Check water temperature with their hands, not their feet.
- c. Inspect their feet daily.
- d. All of the above.
Answer: d. All of the above.
32. The management of hypertension and dyslipidemia in patients with diabetes is crucial for preventing:
- a. Microvascular complications.
- b. Macrovascular complications.
- c. Hypoglycemia.
- d. DKA.
Answer: b. Macrovascular complications.
33. The use of an SGLT2 inhibitor in a patient with T2DM and CKD can:
- a. Worsen renal function.
- b. Slow the decline in GFR.
- c. Increase the risk of hypoglycemia significantly.
- d. Cause weight gain.
Answer: b. Slow the decline in GFR.
34. Which of the following best describes diabetic autonomic neuropathy affecting the cardiovascular system?
- a. Resting tachycardia and orthostatic hypotension.
- b. Bradycardia.
- c. Normal blood pressure response to exercise.
- d. A decreased risk of silent myocardial ischemia.
Answer: a. Resting tachycardia and orthostatic hypotension.
35. A comprehensive diabetes care visit should include:
- a. A review of blood glucose logs.
- b. A physical foot exam.
- c. A blood pressure check.
- d. All of the above.
Answer: d. All of the above.
36. The pathophysiology of diabetic nephropathy is covered in the renal system module of Patient Care 4.
- a. True
- b. False
Answer: a. True
37. Which of the following is a symptom of peripheral artery disease (PAD), a macrovascular complication?
- a. Numbness and tingling in the hands.
- b. Intermittent claudication (leg pain with exertion).
- c. Vision changes.
- d. Nausea and vomiting after meals.
Answer: b. Intermittent claudication (leg pain with exertion).
38. The management of cardiovascular disease is a major topic in the Patient Care 3 course.
- a. True
- b. False
Answer: a. True
39. A patient with diabetes should be screened for dyslipidemia:
- a. Only if they have a heart attack.
- b. At the time of diagnosis and periodically thereafter.
- c. Every 10 years.
- d. Never, as it is not a concern.
Answer: b. At the time of diagnosis and periodically thereafter.
40. An active learning session covering diabetes complications is part of which course?
- a. PHA5787C Patient Care 5
- b. PHA5163L Professional Skills Lab 3
- c. PHA5781 Patient Care I
- d. PHA5782C Patient Care 2
Answer: a. PHA5787C Patient Care 5
41. The primary treatment for proliferative diabetic retinopathy is:
- a. Aspirin therapy.
- b. Intensive glycemic control and laser photocoagulation therapy.
- c. Annual eye exams only.
- d. High-dose statin therapy.
Answer: b. Intensive glycemic control and laser photocoagulation therapy.
42. Which of the following is NOT a risk factor for diabetic foot ulcers?
- a. Peripheral neuropathy
- b. Peripheral artery disease
- c. Foot deformities
- d. Excellent glycemic control
Answer: d. Excellent glycemic control
43. A key part of managing diabetic complications is:
- a. A multifactorial approach targeting glucose, blood pressure, and lipids.
- b. Focusing only on A1c.
- c. Treating complications only after they become severe.
- d. A single medication.
Answer: a. A multifactorial approach targeting glucose, blood pressure, and lipids.
44. A pharmacist’s role in preventing complications involves identifying patients who are not meeting their “ABC” goals.
- a. True
- b. False
Answer: a. True
45. Which of the following is a macrovascular complication?
- a. Nephropathy
- b. Stroke
- c. Neuropathy
- d. Retinopathy
Answer: b. Stroke
46. Tight blood pressure control in patients with diabetes has been shown to reduce the risk of:
- a. Both microvascular and macrovascular complications.
- b. Only microvascular complications.
- c. Only macrovascular complications.
- d. Only hypoglycemia.
Answer: a. Both microvascular and macrovascular complications.
47. A patient with diabetes who has a previous myocardial infarction should be on aspirin for:
- a. Primary prevention.
- b. Secondary prevention.
- c. Pain relief only.
- d. Aspirin is contraindicated.
Answer: b. Secondary prevention.
48. An active learning session on diabetes complications is part of which course module?
- a. Module 1: Diabetes Mellitus
- b. Module 3: Women’s Health
- c. Module 4: Medication Safety
- d. Module 8: Men’s Health
Answer: a. Module 1: Diabetes Mellitus
49. The overall management of preventing diabetic complications is a:
- a. One-time intervention.
- b. Lifelong process of risk factor management and regular screenings.
- c. Responsibility of the patient only.
- d. Responsibility of the endocrinologist only.
Answer: b. Lifelong process of risk factor management and regular screenings.
50. The ultimate goal of learning about the chronic complications of diabetes is to:
- a. Help patients prevent or delay these complications to improve their length and quality of life.
- b. Memorize a list of all possible complications.
- c. Pass the final exam.
- d. Be able to order all the necessary screening tests.
Answer: a. Help patients prevent or delay these complications to improve their length and quality of life.
